Oxidative modification of low-density lipoprotein enhances mesangial cell protein synthesis and gene expression of extracellular matrix proteins

American Journal of Nephrology

Volumn 18, Issue 4, 1998, Pages 344-350

  Roh, Daeyoung D ^a   Kamanna, Vaijinath S ^b   Kirschenbaum, Michaela ^b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

Atherogenic lipoproteins; Extracellular matrix; Fibronectin; Laminin; Low density lipoprotein; Mesangial cells; Minimally modified LDL; Oxidative modification of LDL; Oxidized LDL

Indexed keywords

FIBRONECTIN; LAMININ; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; SCLEROPROTEIN;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CELL PROLIFERATION; CELL TRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; GENE EXPRESSION; GLOMERULOPATHY; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; LIPID OXIDATION; MESANGIUM CELL; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SIMIAN VIRUS 40;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELLS, CULTURED; FIBRONECTINS; GENE EXPRESSION; GLOMERULAR MESANGIUM; HUMANS; LAMININ; LIPOPROTEINS, LDL; MICE; OXIDATION-REDUCTION; RNA, MESSENGER;

EID: 0031780731     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000013363     Document Type: Article

References (49)

1. Moorhead JF, Chan MK, El Nahas M, Varghese Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet 1982;ii:1309-1311.
2. Avram MM: Similarities between glomerular sclerosis and atherosclerosis in human renal biopsy specimens: A role for lipoprotein glomerulopathy. Am J Med 1989;87:5/39N-5/41N
3. Diamond JR: Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 1991;39:529-534.
4. Grond J, Van Goor H, Elema JD: Histochemical analysis of focal segmental hyalinosis and sclerosis lesions in various rat models of experimental nephrotic syndrome. Kidney Int 1986; 29:945-946.
5. Kamanna VS, Roh DD, Kirschenbaum MA: Atherogenic lipoproteins: Mediators of glomerular injury. Am J Nephrol 1993,13:1-5.
6. Kasiske BL, O'Donnell MP, Schmitz PG, Kim Y, Keane WF: Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990; 37:880-891.
7. Diamond JR, Karnovsky MJ: Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. Kidney Int 1987; 32:671-677.
8. Keane WF, Kasiske BL, O'Donnell MP: Lipids and progressive glomerulosclerosis: A model analogous to atherosclerosis. Am J Nephrol 1988;8:261-271.
9. Kamanna VS, Kirschenbaum MA: Association between very low density lipoprotein and glomerular injury in Zucker obese rats. Am J Nephrol 1993;13:53-58.
10. Al-Shebeb T, Frohlich JIR, Magil AB: Glomerular disease in hypercholesterolemic guinea pigs: A pathogenetic study. Kidney Int 1988; 33:498-507.
11. Kasiske BL, O'Donnell MP, Clearly MP, Keane WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988;33:667-672.
12. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rats 5/6 nephrectomy model of chronic renal failure. Circ Res 1988;62:367-374.
13. Harris KPG, Purkerson ML, Yates J, Klahr S: Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 1990; 15:16-26.
14. Kamanna VS, Pai R, Pai V, Kirschenbaum MA: Effect of atherogenic lipoproteins (LP) on ICAM-1-mediated monocyte(MØ) adhesion to mesangial cells (MC). J Am Soc Nephrol 1994; 6:693A.
15. Ha H, Pai R, Kamanna VS, Kirschenbaum MA: Oxidatively modified (ox)-LDL stimulates monocyte (MØ) adhesion to glomerular endothelial cells (EC) mediated by ICAM-1. Am Soc Nephrol 1995;6;830A.
16. Pai R, Kirschenbaum MA, Kamanna VS: Low-density lipoprotein stimulates the expression of macrophage colony-stimulating factor in murine glomerular mesangial cells. Kidney Int 1995;48:1254-1262.
17. Kamanna VS, Pai R, Roh DD, Kirschenbaum MA: Oxidative modification of low-density lipoprotein enhances murine mesangial cell cytokines associated with monocyte migration, differentiation and proliferation. Lab Invest 1996;74:1067-1079.
18. Roh DD, Pai R, Bassa B, Kamanna VS. Kirschenbaum MA: Mesangial cell (MC) activation with oxidized (ox)-LDL stimulates hematopoietic colony formation and monocyte (MØ) proliferation by increasing M-CSF gene expression. J Am Soc Nephrol 6:851A, 1995.
19. Ha H, Bassa B, Pai R, Kirschenbaum MA, Kamanna VS: Role of atherogenic lipoproteins on mesangial cell (MC) proliferation and PDGF gene expression. J Am Soc Nephrol 1995;6:792A.
20. Rovin BH, Tan LC; LDL stimulate mesangial fibronectin production and chemoattractant expression. Kidney Int 1993;43:218-225.
21. Pai R, Kamanna VS, Kirschenbaum MA: Atherogenic lipoproteins enhance mesangial cell transforming growth factor (TGF)-β gene expression and collagen synthesis. J Am Soc Nephrol 1993;5:474A.
22. Cushing SD, Berliner JA, Valente JA, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM: Minimally modified low density lipoprotein induces monocyte chemotactic protein-1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990;87:5134-5138.
23. Ihm CG, Lee GS, Nast CC, Artishevsky A, Guillermo R, Levin PS, Glassock RJ, Adler SG: Early increased renal procollagen alpha 1 (IV) mRNA levels in streptozotocin induced diabetes. Kidney Int 1992;41:768-777.
24. Fine LG, Ong ACM, Norman JT: Mechanisms of tubulo-interstitial injury in progressive renal diseases. Eur J Clin Invest 1993;23:259-265.
25. Goyal M, Wiggins RC: Fibronectin mRNA and protein accumulation, distribution, and breakdown in rabbit anti-glomerular basement membrane disease. J Am Soc Nephrol 1991;1: 1334-1342.
26. Scheinman JI, Tanaka H, Haralson MA: Effects of transforming growth factor-β on collagen synthesis by normal rat kidney epithelial cells. Am J Pathol 1992;140:45-55.
27. Lee DM, Valente AJ, Kuo WH, Maeda H: Properties of apolipoprotein B in urea and in aqueous buffers: The use of glutathione and nitrogen in its solubilization. Biochem Biophys Acta 1981;666:133-146.
28. Havel RJ, Eder HA, Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-1353.
29. Lowry OH; Roscbrough MJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
30. Chomczynski P, Sacchi N: Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Chem 1987;162:156-159.
31. Sambrook J, Fritsch EF, Maniatis T: Extraction, purification and analysis of mRNA. Mol Cloning 1989;1:7.3-7.84.
32. Tsang VC, Peralta JM, Simons AR: Enzyme-linked immunoelectrotransfer blot technique for studying the specificities of antigens and antibodies separated by gel electrophoresis. Meth Enzymol 1983;92:377-391.
33. Studer RK, Craven PA, DeRuberti FR: Low-density lipoprotein stimulation of mesangial cell fibronectin synthesis: Role of protein kinase C and transforming growth factor-β. J Lab Clin Med 1995;125:86-95.
34. Liao F, Berliner JA, Mehrabian M, Navab M, Demer LL, Lusis AJ, Fogelman AM: Minimally modified low density lipoprotein is biologically active in vivo in mice. J Clin Invest 1991; 87:2253-2257.
35. Lee HS, Lee JS, Koh HI, Ko KW: Intraglomerular lipid deposition in routine biopsies. Clin Nephrol 1991;36:67-75.
36. Sato H, Suzuki S, Kobayashi H, Ogino S, Inomata A, Krakawa M: Immunohistological localization of apolipoproteins in the glomeruli in renal disease: Specifically apo B and apo E. Clin Nephrol 1991;36:127-133.
37. Magil AB, Frohlich JJ, Innis SM, Steinbrecher WP: Oxidized low density lipoprotein in experimental focal glomerulosclerosis. Kidney Int 1993;43:1243-1250.
38. Quinn MT, Parthasarathy S, Fong LG, Steinberg D: Oxidative modified low density lipoproteins. A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987; 84:2995-2998.
39. Keane WF, O'Donnell MP, Kasiske BL, Kim Y: Oxidative modification of low density lipoproteins by mesangial cells. J Am Soc Nephrol 1993;4:187-194.
40. Dasgupta A, Hussain S, Ahmad S: Increased lipid peroxidation in patients on maintenance hemodialysis. Nephron 1992;60:56-59.
41. Richard MJ, Arnaud J, Jurkovitz C, Hachache T, Meftahi H, Lapone F, Foret M, Favier A, Cordonnier D: Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron 1991;57:10-15.
42. Martin GR, Klemman HK, Terranova VP, Ledbetter S, Hassel JR: The regulation of basement membrane formation and cell-matrix interactions by defined supramolecular complexes. CIBA Found Symp 1984;108:197-212.
43. Mauch C, Krieg T: Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis. Rheum Dis Clin N Am 1990;16:93-107.
44. Nakagawa S, Pawelek P, Grinnell F: Extracellular matrix organization modulates fibroblast growth and growth factor responsiveness. Exp Cell Res 1989;182:572-582.
45. Seppa HEJ, Yamada KM, Seppa ST, Silver MH: The cell binding fragment of fibronectin is chemotactic for fibroblasts. Cell Biol Int Rep 1981;5:813-819.
46. Terranova VP, Aumailley M, Sultan LH, Martin GR, Kleinman HK: Regulation of cell attachment and cell number by fibronectin and laminin. J Cell Physiol 1986;127:473-479.
47. Bitterman PB, Rennard SI, Adelberg S, Crystal RG: Role of fibronectin as a growth factor for fibroblasts. J Cell Biol 1983;97:1925-1932.
48. Yamada KM: Fibronectin and other cell interactive glycoproteins; in Hay ED (ed): Cell Biology of Extracellular Matrix, ed 2. New York, Plenum Press, 1991, pp 111-139.
49. Yamada KM: Cell surface interactions with extracellular materials. Ann Rev Biochem 1983;52:761-799.